According to our previous study, considerable evidences showed that a liver lipid droplet-associated protein 17β-HSD13 contribute to the development of liver disease. To understand the basis for this, we generated and studied transgenic mice that express human hsd17b13 specifically in hepatocytes (L-h17B13 mice).We examined the hepatic expression of several genes involved in fatty acid synthesis and oxidation in L-h17B13 mice. mRNA levels of three enzymes involved in fatty acid synthesis (SREBP-1c, fatty acid synthase [FAS], and ACC) were significantly increased L-h17B13 mice. The mRNA levels of peroxisome proliferator-activated receptor α (PPARα), a transcription factor that promotes fatty acid oxidation and its target gene, acyl-CoA oxidase (ACOX) and medium-chain acyl-CoA dehydrogenase (MCAD), also higher in L-h17B13 mice. mRNA levels of carnitine palmitoyltransferase (CPT1a), a protein involved in translocating fatty acids into the mitochondria for oxidation, was higher in L-h17B13 mice. ApoB, a lipid secretion related gene, was markedly reduced in L-h17B13 mice. Strikingly, male liver-specific h17β-HSD13 mice fed a standard chow diet display significantly elevated hepatic triglyceride levels at 3-4 months of age compared to matched littermate controls. When mice were fed a high-fat diet, this hepatic phenotype, as well as other metabolic phenotypes (obesity and glucose intolerance), worsened. Our investigations establish that 17β-HSD13 specifically overexpressed in mice hepatocytes induces hepatic steatosis and metabolic disorders.

Disclosure

W. Su: None. Y. Guan: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.